Innovative Paradigms for ART: Implementation Insights From an Expert Panel
  • CME

Watch this on-demand Webcast of a CCO symposium at IAS 2019 to gain expert perspectives on evolving paradigms in ART, including two-drug regimens and long-acting injectable therapy. Learn from an international faculty panel as they engage in detailed discussions about novel ART approaches.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Program Director
Andrea Mantsios, PhD
Anthony M. Mills, MD
Omar Sued, MD, PhD
Babafemi Taiwo, MBBS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: August 26, 2019 Expiration: August 25, 2020
Multimedia Innovative Paradigms for ART: Implementation Insights From an Expert Panel
This program is divided into short segments which you can review from the Activity landing page.
Part 1: New Paradigms for ART (16 mins)
Learn topline data on innovative regimens
Launch Part 1: New Paradigms for ART (16 mins)
Part 2: How Confident Are We With the Efficacy and Safety of Oral Two-Drug Regimens? (12 mins)
Learn detailed information on recent studies
Launch Part 2: How Confident Are We With the Efficacy and Safety of Oral Two-Drug Regimens? (12 mins)
Part 3: Should I Consider Two-Drug Regimens for Most Patients in My Practice or for Just a Select Few? (6 mins)
Hear the panel’s thoughts on when to consider oral two-drug regimens
Launch Part 3: Should I Consider Two-Drug Regimens for Most Patients in My Practice or for Just a Select Few? (6 mins)
Part 4: Is Baseline Resistance Testing Important for Two-Drug Regimens? (16 mins)
Explore whether two-drug regimens are less forgiving of adherence lapses than are three-drug regimens
Launch Part 4: Is Baseline Resistance Testing Important for Two-Drug Regimens? (16 mins)
Part 5: LA ART: Will the Positive Clinical Trial Results Translate to Long-term Efficacy/Safety and Real-World Experience? (12 mins)
Weigh the evidence on long-acting injectable ART
Launch Part 5: LA ART: Will the Positive Clinical Trial Results Translate to Long-term Efficacy/Safety and Real-World Experience? (12 mins)
Part 6: What Have Patients’ Experiences Been on LA Therapy? (16 mins)
Hear about patents’ experiences in their own words
Launch Part 6: What Have Patients’ Experiences Been on LA Therapy? (16 mins)
Part 7: What Are the Challenges of LA Injectable ART for the Provision of HIV Care? (13 mins)
Watch the panel discuss implementation challenges
Launch Part 7: What Are the Challenges of LA Injectable ART for the Provision of HIV Care? (13 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate innovate ART strategies into the management of persons with HIV infection based on key data and practice guidelines
  • Appraise two-drug vs three-drug treatment strategies in the care of persons with HIV infection
  • Devise strategies to incorporate the use of long-acting ART as a treatment option for appropriate candidates, once available

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
ViiV Healthcare

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has received funds for research support, consulting fees, and fees for non-CME/CE services from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV.

Faculty

Andrea Mantsios, PhD

Research Fellow
Center for Health, Risk, and Society
American University
Washington, DC

Andrea Mantsios, PhD, has disclosed that she has received funds for research support from ViiV.
Anthony M. Mills, MD

President, Southern California Men's Medical Group
CEO and CMO, Men's Health Foundation
President & Clinical Research Director, Mills Clinical Research
Assistant Professor of Clinical Medicine
University of California, Los Angeles
Los Angeles, California

Anthony M. Mills, MD, has disclosed that he has received consulting fees and funds for research support from Gilead Sciences, Janssen, Merck, and ViiV.
Omar Sued, MD, PhD

Director, Research Department
Fundación Huésped
Buenos Aires, Argentina

Omar Sued, MD, PhD, has disclosed that he has received consulting fees from ViiV and other financial or material support from Gilead Sciences.
Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, and ViiV.

Staff

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who provide care for HIV-infected patients.

Goal

The goal of this activity is to improve participants’ knowledge and competence regarding the clinical role of innovative antiretroviral regimens.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 26, 2019, through August 25, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?